Re­ject­ed: Af­ter pay­ing $80M to ac­quire it, Mallinck­rodt's jaun­dice drug snubbed by FDA's ad­vi­so­ry com­mit­tee

Mallinck­rodt just got a big thumbs down from the FDA’s ad­vi­sors who say da­ta on the com­pa­ny’s new­ly-ac­quired jaun­dice drug isn’t con­vinc­ing a ma­jor­i­ty of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.